Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Gasparini G, Gattuso D, Morabito A, Longo R, Torino F, Sarmiento R, Vitale S, Gamucci T, Mariani L. Gasparini G, et al. Among authors: torino f. Oncologist. 2005 Oct;10(9):710-7. doi: 10.1634/theoncologist.10-9-710. Oncologist. 2005. PMID: 16249351 Free article. Clinical Trial.
Unusual reaction to chlorambucil: a case report.
Pietrantonio F, Moriconi L, Torino F, Romano A, Gargovich A. Pietrantonio F, et al. Among authors: torino f. Cancer Lett. 1990 Nov 5;54(3):109-11. doi: 10.1016/0304-3835(90)90030-2. Cancer Lett. 1990. PMID: 2224838
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not).
Corsello SM, Salvatori R, Barnabei A, De Vecchis L, Marchetti P, Torino F. Corsello SM, et al. Among authors: torino f. Cancer Chemother Pharmacol. 2013 Aug;72(2):489-90. doi: 10.1007/s00280-013-2213-y. Epub 2013 Jun 19. Cancer Chemother Pharmacol. 2013. PMID: 23779068 No abstract available.
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F, Spada A, Zancan M, De Sio L, Caputo A, Cognetti F, Lambiase A, Amadori D. Gasparini G, et al. Among authors: torino f. Breast Cancer Res Treat. 2007 Mar;101(3):355-65. doi: 10.1007/s10549-006-9306-9. Epub 2006 Jul 19. Breast Cancer Res Treat. 2007. PMID: 16850247 Clinical Trial.
91 results